文献速递免疫规划

中国儿童两种肠道病毒71型灭活疫苗互换性的IV期开放标签随机对照试验

Interchangeability of two Enterovirus 71 inactivated vaccines in Chinese children: A phase IV, open-label, and randomized controlled trial.
PubMed 文献 · Vaccine · 2020-02-14

在中国6-35月龄儿童中开展IV期开放标签随机对照试验,将300名儿童按1:1:1:1随机分配至四种EV71疫苗接种程序(两种单一厂家全程接种,两种两厂家混合接种),评估互换性与安全性。结果显示四组血清阳转率98.4%-100.0%且组间无显著差异,D组(首剂医学生物学研究所疫苗、第二剂科兴疫苗)几何平均滴度较高,安全性相似,未报告与接种相关的严重不良事件。

要点

  • 四组EV71中和抗体血清阳转率98.4%-100.0%,组间无显著差异。
  • D组(首剂CAMS疫苗、第二剂科兴疫苗)几何平均滴度高于其他组。
  • 四组安全性相似,未报告与接种相关的严重不良事件。

核心结论

  • 两种厂家EV71疫苗互换完成免疫程序显示出良好的免疫原性和安全性。
  • 抗体应答水平可能因两种厂家EV71疫苗的接种顺序而异。

研究设计与样本

  • IV期开放标签随机对照试验,2018年11月至2019年1月在中国6-35月龄儿童中开展。
  • 300名儿童按1:1:1:1随机分配至四种接种程序:两种单一厂家全程接种,两种两厂家混合接种。
  • 免疫原性在意向方案队列中评估,安全性在总接种队列中评估。

主要发现

  • 共纳入并随机300名儿童,其中89.0%(267/300)纳入免疫原性分析的全分析集。
  • 四组EV71中和抗体血清阳转率范围为98.4%至100.0%,组间无显著差异。
  • 与其他组相比,D组(首剂中国医学科学院医学生物学研究所疫苗、第二剂科兴疫苗)几何平均滴度较高。
  • 四组安全性特征相似,未报告与接种相关的严重不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In China, three inactivated Enterovirus 71 (EV71) vaccines have been approved. Although the vaccines in an immunization series should be from a single manufacture, children sometimes have to receive EV71 vaccines from more than one manufacturers. The aim of this study was to evaluate the interchangeability and safety of vaccination with EV71 vaccines from two manufacturers among Chinese children. METHODS: We conducted an open label and randomized controlled study among children aged 6-35 months from November 2018 to January 2019. The participants were randomly assigned (1:1:1:1) to receive EV71 vaccines in one of the four different schedules (two using a single vaccine for all doses from one manufacture, and two mixed schedules using vaccines from two manufactures). Blood samples were collected pre-vaccination (Day 0) and one month after the second dose (Day 60) for neutralizing antibody assay. Immunogenicity was assessed in the per-protocol cohort and safety was assessed in the total vaccinated cohort. RESULTS: A total of 300 children were enrolled and randomized, of whom 89.0% (267/300) were included in the per-protocol cohort for immunogenicity analysis. The seroconversion rates of the EV71 neutralizing antibody in four groups ranged from 98.4% to 100.0%, and were not significantly different among the groups. Compared with other groups, geometric mean titer was higher in group D, in which the participants received Institute of Medical Biology Chinese Academy of Medical Sciences (CAMS) vaccine in the first dose and the Sinovac vaccine in the second dose. Safety profiles were similar among the four groups and no serious adverse events related to the vaccination were reported. CONCLUSIONS: Interchangeability of EV71 vaccines from two manufactures to complete an immunization series showed good immunogenicity and safety. The antibody response levels may vary by vaccination sequences of EV71 vaccines from the two manufacturers. TRIAL REGISTRATION: ClinicalTrials.govNCT03873740.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Xu Q, Cao Q, Yang W, et al. Interchangeability of two Enterovirus 71 inactivated vaccines in Chinese children: A phase IV, open-label, and randomized controlled trial. Vaccine. 2020. PMID: 32067817. doi:10.1016/j.vaccine.2020.02.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。